Clinical Trial Search

Primary: Change in the Average Pain Intensity Score for the Overall Low Back Pain on an 11-point Numeric Rating Scale (NRS-3) — -1.6; -1.7 units on a scale

Primary: Change in HbA1c From Baseline — -1.27; -1.04 percentage change in HbA1c — p=<0.001

Primary: Gastric Emptying Half-time (T 1/2) of Solids — 187; 86 minutes — p=<.001

Primary: Change From Baseline in Morning Stiffness Duration at Week 12 as Assessed by Patient Diary — -16.76 minutes

Primary: Least Squares Mean Intraocular Pressure (IOP) at 8AM in the Study Eye — 16.6129; 21.2320 mmHg — p=<0.0001

Primary: Pain Scores Measured by VAS (Visual Analog Scale) at Day 42. — 3.2; 3.9 units on a scale — p=0.7

Primary: Mean Reduction in SNOT-20 Scores — 1.8; 5.5 units on a scale — p=0.23

Primary: Percentage of Participants With Relapse Rate in Groups A and B by Genotype at the End of Follow-up (Part 1) — 22.0; 8.3; 52.7; 30.0 Percentage of participants — p=0.1002

Primary: Occurence Rate of Uveitis Attacks in Participants Before Anti-TNF/GLM Treatment and After the Start of GLM Treatment — 0.08; 0.08 Ratio — p=1.0000

Primary: Mean Heavy Drinking Days Per Week by Medication Group — 1.82; 2.94 Number of heavy drinking days — p=0.001

Primary: Maximal Change in NRS Pain Scores as a Percentage of Baseline NRS Pain Score. — -66.4; -61.3; -81.1; -79.8 percent change from baseline NRS score. — p=0.18

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy — 76.6; 84.2 Percentage of participants

Primary: Serum LDL Cholesterol — 122.2; 113.5 mg/dl

Primary: Mean Percentage Change From Baseline in Physical Function at 1 Year Follow-up Using the Patient Completed Zurich Claudication Questionnaire — -32.31; -37.48 percentage…

Primary: Hepatic Steatosis — 4.0 Percentage of liver fat